# **Special Issue**

# Novel Approaches in Discovery and Design of Antibody-Based Therapeutics

# Message from the Guest Editor

Since the approval of muromonab-CD3 in 1986, antibodies have gone from being widely considered as nothing more than academic curiosities, with insurmountable discovery, development, manufacturing, processing, regulatory, supply chain, delivery and immunogenicity issues, to becoming mainstream and frontline therapeutic options for clinicians.

Since 1976, when the invention of hybridoma solved the issues of product definition and consistency of supply, the technology has advanced rapidly, spanning the fields of molecular biology, structural biology, computer-aided drug design, process biology and, more recently, artificial intelligence, to address ever more unmet patient need.

In this Special Issue, we aim to highlight technological approaches currently being developed and applied to the invention of antibody-based products and look forward to the approval of ever more efficacious and safe medicines that build on the legacy of Orthoclone OKT3.

#### **Guest Editor**

Dr. Alastair Lawson Structural Biology, UCB, 216 Bath Road, Slough SL1 3WE, UK

### Deadline for manuscript submissions

closed (20 January 2023)



an Open Access Journal by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed



mdpi.com/si/110710

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

mdpi.com/journal/ antibodies





an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.5 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

# **Editor-in-Chief**

#### Prof. Dr. Arne Skerra

Institute of Biological Chemistry, Technical University Munich, Emil-Erlenmeyer-Forum 5, 85350 Freising-Weihenstephan, Germany

#### **Author Benefits**

#### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### **Journal Rank:**

CiteScore - Q2 (Drug Discovery)

